AIM IMMUNOTECH INC(NYSEARCA:AIM) stock News

AIM Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得

18 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

21 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

a month ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

2 months ago - By: Benzinga

Uncovering Potential: AIM ImmunoTech's Earnings Preview

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

2 months ago - By: Zacks Investment Research - Mentions: FGEN

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

2 months ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Resumes Trading on NYSE American

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

6 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

6 months ago - By: AIM ImmunoTech Inc.

AIM IMMUNOTECH INC (AIM) Stock News

AIM Latest News, Press Relases and Analysis

AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Uncovering Potential: AIM ImmunoTech's Earnings Preview

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Earnings Scheduled For August 14, 2025

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal